1. Conn, P.J., Lindsley, C.W., Meiler, J. & Niswender, C.M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 13, 692-708 (2014).
2. Sako, Y. et al. TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects. Neuropsychopharmacology 44, 950-960 (2019).
3. O'Neill, M.J., Bleakman, D., Zimmerman, D.M. & Nisenbaum, E.S. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 3, 181-94 (2004).
4. Kew, J.N. & Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179, 4-29 (2005).
5. Boulter, J. et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249, 1033-7 (1990).
6. Keinanen, K. et al. A family of AMPA-selective glutamate receptors. Science 249, 556-60 (1990).
7. Nakanishi, N., Shneider, N.A. & Axel, R. A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron 5, 569-81 (1990).
8. Fletcher, E.J. et al. Cloning, expression and pharmacological characterization of a human glutamate receptor: hGluR4. Receptors Channels 3, 21-31 (1995).
9. Sommer, B. et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249, 1580-5 (1990).
10. Schoft, V.K., Schopoff, S. & Jantsch, M.F. Regulation of glutamate receptor B pre-mRNA splicing by RNA editing. Nucleic Acids Res 35, 3723-32 (2007).
11. Kato, A.S., Siuda, E.R., Nisenbaum, E.S. & Bredt, D.S. AMPA receptor subunit-specific regulation by a distinct family of type II TARPs. Neuron 59, 986-96 (2008).
12. Tomita, S. Regulation of ionotropic glutamate receptors by their auxiliary subunits. Physiology (Bethesda) 25, 41-9 (2010).
13. Sobolevsky, A.I., Rosconi, M.P. & Gouaux, E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462, 745-56 (2009).
14. Derkach, V.A., Oh, M.C., Guire, E.S. & Soderling, T.R. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci 8, 101-13 (2007).
15. Murray, T.K. et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 306, 752-62 (2003).
16. Balaratnasingam, S. & Janca, A. Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 134, 116-24 (2012).
17. Yamada, K.A. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis 5, 67-80 (1998).
18. Beattie, E.C. et al. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci 3, 1291-300 (2000).
19. Ehlers, M.D. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 28, 511-25 (2000).
20. Bai, F., Bergeron, M. & Nelson, D.L. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 44, 1013-21 (2003).
21. Fowler, J.H., Whalley, K., Murray, T., O'Neill M, J. & McCulloch, J. The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J Cereb Blood Flow Metab 24, 1098-109 (2004).
22. Bernard, K. et al. DRUG FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer. CNS Neurosci Ther 16, e193-212 (2010).
23. Mackowiak, M., O'Neill, M.J., Hicks, C.A., Bleakman, D. & Skolnick, P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43, 1-10 (2002).
24. Sasaki, T., Kawai, K., Saijo-Kurita, K. & Ohno, T. Detergent cytotoxicity: simplified assay of cytolysis by measuring LDH activity. Toxicol In Vitro 6, 451-7 (1992).
25. Kessler, M. & Arai, A.C. Use of [3H]fluorowillardiine to study properties of AMPA receptor allosteric modulators. Brain Res 1076, 25-41 (2006).
26. Ward, S.E., Bax, B.D. & Harries, M. Challenges for and current status of research into positive modulators of AMPA receptors. Br J Pharmacol 160, 181-90 (2010).
27. Kaae, B.H. et al. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. Chem Biol 14, 1294-303 (2007).
28. Sukumaran, M. et al. Dynamics and allosteric potential of the AMPA receptor N-terminal domain. EMBO J 30, 972-82 (2011).
29. Jhee, S.S. et al. Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects. J Clin Pharmacol 46, 424-32 (2006).
30. Gates, M., Ogden, A. & Bleakman, D. Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 40, 984-91 (2001).
31. Miu, P. et al. Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40, 976-83 (2001).
32. Yelshanskaya, M.V., Li, M. & Sobolevsky, A.I. Structure of an agonist-bound ionotropic glutamate receptor. Science 345, 1070-4 (2014).
33. Armstrong, N. & Gouaux, E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 28, 165-81 (2000).
34. Zarrinmayeh, H. et al. [3H]N-2-(4-(N-benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand. J Med Chem 44, 302-4 (2001).
35. Otwinowski, Z. & Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode Methods in Enzymology 276, 307-326 (1997).
36. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67, 355-67 (2011).
37. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
38. Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21 (2010).
39. Traynelis, S.F. et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62, 405-96 (2010).
40. Hayashi, Y. et al. A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol Psychiatry 16, 1155-8 (2011).
41. Shiraishi, E., Suzuki, K., Harada, A., Suzuki, N. & Kimura, H. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models. J Pharmacol Exp Ther 356, 587-95 (2016).